2.87

5.28% -0.16

Pre-market: 2.82 -0.05 -1.74%

Replimune Group Inc (REPL)

Overview News Price History Option Chain Financials Discussions Forecast

Replimune Group Inc stock is traded at $2.87, with a volume of 7.62M. It is down -5.28% in the last 24 hours and down -65.87% over the past month. Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Previous Close:

$3.03

Open:

$3.02

24h Volume:

7.62M

Relative Volume:

1.71

Market Cap:

$236.98M

Revenue:

Net Income/Loss:

$-314.85M

P/E Ratio:

-0.8011

EPS:

-3.5825

Net Cash Flow:

$-283.27M

1W Performance:

+11.67%

1M Performance:

-65.87%

6M Performance:

-66.55%

1Y Performance:

-71.33%

1-Day Range:

$2.52

$3.09

1-Week Range:

$2.335

$3.14

52-Week Range:

$1.50

$13.24

Replimune Group Inc Stock (REPL) Company Profile

Name

Replimune Group Inc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

(781) 222-9600

Address

500 UNICORN PARK, WOBURN, MA

Employee

479

Twitter

@Replimune

Next Earnings Date

2026-05-28

Latest SEC Filings

REPL's Discussions on Twitter

Compare REPL vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
REPL Replimune Group Inc	2.87	236.98M	0	-314.85M	-283.27M	-3.5825
VRTX Vertex Pharmaceuticals Inc	424.36	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.06B	5.36B	287.73M	924.18M	2.5229

Replimune Group Inc Stock (REPL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-13-26	Downgrade	BMO Capital Markets	Market Perform → Underperform
Apr-13-26	Downgrade	H.C. Wainwright	Buy → Sell
Apr-13-26	Downgrade	JP Morgan	Neutral → Underweight
Apr-13-26	Downgrade	Jefferies	Buy → Hold
Apr-13-26	Downgrade	Leerink Partners	Outperform → Market Perform
Apr-13-26	Downgrade	Wedbush	Outperform → Neutral
Apr-10-26	Downgrade	Piper Sandler	Overweight → Neutral
Nov-03-25	Upgrade	BMO Capital Markets	Underperform → Market Perform
Oct-27-25	Upgrade	H.C. Wainwright	Neutral → Buy
Oct-20-25	Upgrade	JP Morgan	Underweight → Neutral
Oct-20-25	Upgrade	Leerink Partners	Market Perform → Outperform
Oct-20-25	Upgrade	Piper Sandler	Neutral → Overweight
Oct-20-25	Upgrade	Wedbush	Neutral → Outperform
Sep-19-25	Downgrade	JP Morgan	Neutral → Underweight
Jul-30-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Jul-23-25	Downgrade	BMO Capital Markets	Outperform → Underperform
Jul-23-25	Downgrade	Barclays	Overweight → Equal Weight
Jul-23-25	Downgrade	H.C. Wainwright	Buy → Neutral
Jul-22-25	Downgrade	JP Morgan	Overweight → Neutral
Jul-22-25	Downgrade	Leerink Partners	Outperform → Market Perform
Jul-22-25	Downgrade	Piper Sandler	Overweight → Neutral
Jul-22-25	Downgrade	Wedbush	Outperform → Neutral
Jun-20-25	Initiated	Cantor Fitzgerald	Overweight
Aug-28-24	Initiated	ROTH MKM	Buy
Apr-17-23	Resumed	Piper Sandler	Overweight
Nov-19-21	Initiated	Piper Sandler	Overweight
Oct-15-21	Resumed	BTIG Research	Buy
Nov-17-20	Initiated	BTIG Research	Buy
Nov-02-20	Initiated	Jefferies	Buy
Oct-15-20	Upgrade	H.C. Wainwright	Neutral → Buy
Jul-01-20	Downgrade	H.C. Wainwright	Buy → Neutral
May-05-20	Initiated	Barclays	Overweight
Sep-04-19	Initiated	ROTH Capital	Buy
Jul-23-19	Initiated	Chardan Capital Markets	Buy
Jul-12-19	Upgrade	JP Morgan	Neutral → Overweight
Jul-08-19	Initiated	H.C. Wainwright	Buy
Apr-25-19	Initiated	Wedbush	Outperform
Jan-23-19	Downgrade	JP Morgan	Overweight → Neutral
Aug-14-18	Initiated	JP Morgan	Overweight
Aug-14-18	Initiated	Leerink Partners	Outperform

View All

Replimune Group Inc Stock (REPL) Latest News

12:39 PM

REPL nosedives as FDA chief stands firm against melanoma treatment: ‘I don’t work for Replimune’ - MSN

12:39 PM

May 05, 2026

FDA Commissioner Makary defends agency’s decision on Replimune’s drug, CNBC reports - hi99.com

May 05, 2026

FDA head Makary defends drug application rejections amid criticism - Seeking Alpha

May 05, 2026

REPL Stock Plunges As FDA Rejects Key Melanoma Therapy - StocksToTrade

May 05, 2026

What's Going On With Replimune Stock On Tuesday? - Benzinga

May 05, 2026

REPL Nosedives As FDA Chief Stands Firm Against Melanoma Treatment: ‘I Don’t Work For Replimune…’ - Stocktwits

May 05, 2026

REPL Stock Plunges As FDA Rejection Triggers Legal And Wall Street Backlash - timothysykes.com

May 05, 2026

FDA Commissioner Makary defends agency's decision on Replimune's drug, CNBC reports - Reuters

May 05, 2026

FDA Commissioner Makary defends agency's decision on Replimune's drug - marketscreener.com

May 05, 2026

Fda's Makary on Replimune's Drug Says If the Clinical Trials Show That It Works, It's Going to Get ApprovedCnbc - marketscreener.com

May 05, 2026

Fda's Makary on Replimune Says Three Indepndent Teams Arrived at the Same ConclusionsCnbc - marketscreener.com

May 05, 2026

Fda's Makary Defends Agency's Decision On Replimune's Cancer Drug -Cnbc - marketscreener.com

May 05, 2026

Replimune plunges after FDA rejects skin cancer drug again - MSN

May 05, 2026

May 03, 2026

REPL stock rallies in anticipation of FDA decision on skin cancer drug - MSN

May 03, 2026

May 01, 2026

FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients - The Cancer Letter

May 01, 2026

Short Interest in Replimune Group, Inc. (NASDAQ:REPL) Grows By 12.8% - MarketBeat

May 01, 2026

Apr 30, 2026